Brca1 deficiency leads to the development of breast cancer. We previously found that Brca1 deficiency activates the Akt oncogenic pathway. Reduced expression of Brca1 was highly correlated with increased activated Akt in human breast cancer samples. Furthermore, activation of Akt1 was involved in Brca1-deficiency-mediated tumorigenesis in mice. Defective homologous recombination (HR) is thought to be a major contributor to tumorigenesis in Brca1 deficiency. Here, we show that Akt1 promotes chromosome instability in Brca1-deficent cells. DNA breaks in Brca1-deficent cells are aberrantly joined into complex chromosome rearrangements by a process dependent on Akt1. Depletion of Akt1 increases HR in Brca1-mutant cells, which is rescued by expression of wild-type, but not mutant Akt1 with deletion of Brca1-binding domain. Mechanistically, activated Akt1 in Brca1-deficient cells impairs Chk1 nuclear localization and subsequently disrupts interaction of Chk1 and Rad51 leading to HR defects. Our results indicate that Brca1 deficiency might activate Akt1 contributing to tumorigenesis through regulation of the Chk1-Rad51 signaling.
INTRODUCTION
The breast cancer susceptibility gene 1 (Brca1) has a key role in both hereditary and sporadic mammary tumorigenesis. 1 However, the reasons why Brca1 deficiency leads to the development of cancer are not clearly understood. The Brca1 protein contains an N-terminal ring domain and C-terminal tandem BRCT motifs that are phospho-protein-binding motifs. The BRCT domains are important for the tumor-suppressor function of Brca1. [2] [3] [4] Most Brca1 mutations result in truncated Brca1 gene products that lack one or both C-terminal BRCT domains. Clinically relevant missense mutations identified at the C-terminus of Brca1 abolish the structure of BRCT and loss of the Brca1-BRCT domains leads to tumor formation in mice. 3, 5 Activation of Akt kinase is one of the most common molecular alterations associated with human malignancy. Increased Akt kinase activity has been reported in most breast cancers. 6, 7 We previously showed that Brca1 deficiency activates the Akt oncogenic pathway. 8 Mutation of Brca1 gene increases the phosphorylation and the kinase activity of Akt. The Brca1-BRCT domains directly bind to phosphorylated Akt (pAkt), leading to its ubiquitination towards protein degradation. Furthermore, we analyzed Brca1/Akt expression in human breast cancer samples and found that reduced expression of Brca1 was highly correlated with increased phosphorylation of Akt. 7 Consistent with the clinical data, depletion of Akt1 significantly reduced tumor formation induced by Brca1 deficiency in mice. Our results indicate that activation of Akt1 is involved in Brca1-deficiency-mediated tumorigenesis.
In the absence of Brca1, homologous recombination (HR) repair and Rad51 foci formation are impaired, 9 ,10 which contributes to genomic instability and tumorigenesis. Because Akt1 is also involved in DNA damage response and HR, 11 therefore, we investigated effects of Akt1 on HR in Brca1-deficient cells. We found that depletion of Akt1 could correct HR defects and chromosomal instability through activating Chk1-Rad51 signaling in Brca1-deficient cells.
RESULTS

Akt1 promotes chromosomal instability in Brca1-deficient cells
We previously found that depletion of Akt1 in Brca1-deficient cells resulted in arrest of cell proliferation and significantly reduced tumorigenesis in mice. 7 Brca1 D11/D11 mice rescued by loss of one or both copies of p53 developed multiple types of tumors. 12 To further investigate the requirement for Akt1 in Brca1-deficient tumorigenesis, Akt1-shRNAs were stably expressed in Brca1 D11/D11 mouse embryo fibroblasts (MEFs) to deplete Akt1 expression (Supplemental Figure S1 ). Depletion of Akt1 significantly reduced colony formation in Brca1 D11/D11 MEFs compared with that of control cells (Supplemental Figure S2) . To test whether depletion of Akt1 inhibits the tumorigenicity associated with Brca1 deficiency, Brca1 D11/D11 MEFs stably expressing either the shGFP or shAkt1 were implanted into SCID mice. As expected, implantation of control shGFP Brca1 D11/D11 MEFs resulted in tumor formation in 19 of 20 mice (95%, Figure 1a) . Expressions of Akt1-sh1 and Akt1-sh2 were sufficient to dramatically suppress tumor development and only 3-4 of 20 mice generated tumors, respectively. In contrast, breast cancer cells MCF7 (Brca1 wild-type) with knockdown of Akt1 resulted in tumor formation in 14-16 of 20 mice (Figure 1a) . Western blot and immunohistochemical analysis of dissected tumors revealed an increased pAkt1 in Brca1
-induced tumors (data not shown), consistent with previous observations. 7 Thus, depletion of Akt1 in Brca1
MEFs results in arrest of cell proliferation and suppression of tumor growth. Brca1 is thought to suppress tumorigenesis by promoting HR, 5,9,10 therefore, we hypothesized that depletion of Akt1 might specifically affect HR in Brca1-deficient cells. To test this, we examined chromosome abnormalities in metaphase spreads from wild-type (WT) and Brca1 D11/D11 with or without Akt1-shRNA expressions. Asymmetric radial chromosome structures, a type of chromatid exchange characteristic of HR deficiency, were found in 8% in Brca1 D11/D11 MEFs (Figure 1b) , consistent with previous reports. 13 We depleted Brca1 by small hairpin RNAs (shRNAs) in normal human fibroblasts IMR90 and radial chromosomes were found in 7-8% in the cells (Supplemental Figure S3) , supporting that Brca1 deficiency induces radial chromosomes. Expressions of shAkt1-A and shAKT-B were sufficient to inhibit formation of radial chromosome and we did not observe radial chromosomes in Brca1 D11/D11 MEFs with Akt1-shRNAs expression. Furthermore, ionizing irradiation (IR) treatment caused a substantial increase of radial chromosomes in both WT and Brca1 D11/D11 MEFs, suggesting that IR promotes radial chromosome formation (Figure 1c) . Depletion of Akt1 significantly decreased formation of radial chromosomes. Taken together, these results suggest that Akt1 promotes chromosomal instability, cellular proliferation and tumorigenesis in Brca1-deficient cells.
Depletion of Akt1 increases HR in Brca1-deficient cells Brca1-deficient cells display HR-defective.
9,10 Therefore, we first examined Rad51 foci formation, a marker of HR, which is impaired in Brca1-deficient cells. 14, 15 WT and Brca1 D11/D11 MEFs with or without expression of Akt1-shRNAs were treated with IR and stained with a Rad51 antibody (Figure 2a) . Analysis of these IRinduced Rad51 foci revealed a diminished response upon depletion of Brca1, consistent with previous observations. 13, 16 shRNA-mediated depletion of Akt1 increased Rad51 foci formation in the absence of Brca1, suggesting that Akt1 may inhibit HR in Figure  S4) . Thus, depletion of Akt1 is able to promote ssDNA formation competent for RPA phosphorylation in Brca1-mutant cells. In addition, knockdown of Akt1 in Brca1 D11/D11 MEFs did not change 53BP1 foci formation (Supplemental Figure S5) , suggesting that different mechanism is involved in the Brca1-mediated HR process.
We demonstrate that the Akt1-HM domain binds to Brca1. 7 To verify the effect of Brca1 and Akt1 on HR process, we performed the rescue experiments. Overexpression of Akt1-S473D, a constitutively active form, decreased Rad51 foci formation in Brca1 D11/D11 MEFs with depletion of Akt1 (Figure 2a) . Expression of Akt1-DHM mutant that does not have the binding domain to Brca1 did not affect Rad51 foci by depletion of Akt1. These results verify that Akt1 is involved in Brca1-mediated HR process.
To further determine the role of Akt1 in HR in Brca1-deficient cells, we used the DR-GFP reporter system, 17 which is designed to measure error-free HR repair of a site-specific break formed by the endonuclease I-SceI. We integrated DR-GPF substrate into WT and Brca1 D11/D11 MEFs with or without expressions of Akt1-shRNAs and found that HR in Brca1 D11/D11 MEFs was reduced relative to the WT cells (three-fold, Figure 2b ). HR in Brca1 D11/D11 cells upon depletion of Akt1 was increased to the similar level in the WT cells. Akt1-S473D, but not DHM mutant, decreased HR levels in Brca1
MEFs with depletion of Akt1 (Figure 2b) . Thus, we conclude that depletion of Akt1 increases HR in Brca1-deficient cells.
Chk1 nuclear localization by Akt1 is responsible for radial chromosome formation and HR defect in Brca1-mutant cells. The cell cycle checkpoint kinase Chk1 is required for HR 18 and Akt regulates Chk1 cellular localization. 19 To determine whether Akt1 regulates HR by Chk1 in Brca1-deficient cells, we examined Chk1 localization in WT and Brca1 D11/D11 MEFs. Using immunefluorescence with a pChk1 antibody, we found a significant reduction in nuclear pChk1 staining in Brca1 D11/D11 MEFs (Figure 3a) . Moreover, depletion of Akt1 in Brca1 D11/D11 MEFs rescued nuclear staining of pChk1, 
Akt1 inhibits HR in
To further investigate the function of Chk1 on HR in Brca1-deficient cells, we generated lentiviral vectors carrying shRNAs targeted to Chk1. When an equal titer of supernatant from each Chk1 shRNA construct or a vector control was transduced into Brca1 D11/D11 MEFs, almost all the cells became puromycin resistant, showing high transduction efficiency in the experimental system. After 48 h of infection with Chk1-sh1 and Chk1-sh2, endogenous Chk1 protein levels were reduced by approximately 80-90% compared with controls (Supplemental Figure S6 ). Using these Chk1-shRNAs, we examined radial chromosomes and HR level in Brca1 D11/D11 MEFs. Chk1 depletion did not change both radial chromosomes and HR level in Brca1 D11/D11 MEFs (data not shown). Double depletions of Akt1 and Chk1 increased redial chromosomes and decreased HR level (Figures 3b and c) , suggesting that Akt1 inhibits the nuclear localization of Chk1 leading to HR defective and chromosome instability in Brca1-deficient cells.
Akt1-Chk1-Rad51 signaling is involved in HR defective in Brca1-deficient cells Chk1 is required for Rad51 foci formation. 18 First, we examined IRinduced Rad51 foci formation in Brca1-deficent cells with depletion of Chk1. Knockdown of Chk1 did not change Rad51 foci formation in Brca1 D11/D11 MEFs (data not shown). However, depletion of Chk1 impaired Rad51 foci formation, whereas Brca1 D11/D11 MEFs with expressing Akt1-shRNA showed the increased Rad51 foci (Figure 4a ), suggesting that effect of Chk1 on Rad51 foci formation is dependent on Akt1. For further analysis of Chk1 and Rad51 cellular localization in Brca1 D11/D11 MEFs, cytoplasmic and nuclear fractions were prepared and analyzed by Western blotting. Decreased pChk1 levels were found in the nuclei of Brca1 D11/D11 MEFs compared with Brca1 WT cells (Figure 4b ), whereas depletion of Akt1 rescued pChk1 expression in the nuclei. Rad51 levels also decreased in the nuclei and increased in the cytoplasma of Brca1 D11/D11 MEFs and knockdown of Akt1 rescued these alterations. These observations indicate that Akt1 induces cytoplasmic retention of Chk1 and Rad51 in Brca1 D11/D11 MEFs. Next, we examined whether Akt1 affects interaction of Chk1 and Rad51 in Brca1-deficient cells, as Chk1 physically interacts with Rad51 to regulate HR. 18 Using immunoprecipitation, we found that pChk1 associated with Rad51 in Brca1-WT cells (Figure 4c ), consistent with previous observation. 18 However, we did not detect pChk1 protein in Rad51 immunocomplex in Brca1 D11/D11 MEFs. Depletion of Akt1 rescued association of pChk1 and Rad51, suggesting that these protein-protein interactions are dependent on Akt1.
DISCUSSION
The increased Akt1 kinase activity in Brca1-deficient tumors suggests that Akt1 is involved in Brca1-deficiency-mediated tumorigenesis. Depletion of Akt1 decreases Brca1-deficient tumor formation supporting this notion. Here, we provide a functional link between the Akt1-Chk1 pathway and HR in Brca1-deficient cells. Our data indicate that loss of Akt1 restores HR to Brca1-deficient cells and increased pAkt1 in Brca1-deficient cells induces 
interaction of Chk1 and Rad51 in the nuclei. Thus, defects in Akt1-Chk1-Rad51 signaling result in HR defective and chromosome instabilities, consequently leading to Brca1-deficient tumorigenesis.
The precise role of Akt in HR is a matter of ongoing investigation. Previous work has shown that Akt1 inhibits HR by inducing cytoplasmic retention of Brca1 and Rad51 in Brca1-proficient cells. 11 Here, we show that this suppression still functions in the absence of Brca1 and more importantly, loss of Akt1 can promote HR in the absence of Brca1. Our results support a notion that Akt1 cannot simply suppress HR by sequestering Brca1 to the cytoplasm because depletion of Akt1 can restore HR to Brca1-deficient cells. Both Brca1 and Pten deficiencies activate the Akt1 oncogenic pathway and induce tumor formation. Lack of Pten sequesters Akt1-Chk1 and initiates genetic instability, 19 implicating that Akt1-Chk1 signaling might be also responsible for genetic instability in Brca1-deficient cells. Defective HR contributes to genetic instability and tumorigenesis in Brca1 deficiency. Interactions of Chk1 and Rad51 are required for HR, 18 suggesting that the Chk1-Rad51 pathway might be dysfunctional in Brca1-deficient cells. We provide evidence that Brca1 deficiency activates Akt1 to sequester blocking Chk1-Rad51 signaling and inducing defective HR, genetic instability and tumor formation. These results support a model of molecular tumorigenesis that Brca1 deficiency may activate the Akt1-Chk1-Rad51 pathway to generate cancer.
Recent reports show that 53BP1 loss rescues Brca1 deficiency and is associated with triple-negative and Brca1-mutated breast cancer. 13, 16 53BP1 inhibits HR in Brca1-deficient cells by blocking resection of DNA breaks. We show that depletion of Akt1 can restore HR to Brca1-deficient cells-this is somewhat similar to the ability of loss of 53BP1 to restore HR to Brca1-deficient cells. Loss of Akt1 does not alter 53BP1 foci formation in Brca1-deficient cells, supporting that Akt1 and 53BP1 independently regulate the HR process in Brca1-deficient cells. 53BP1 and Brca1 may regulate the choice between HR and non-homologous end joining. One critical function for Brca1 might be to remove end-joining proteins such as 53BP1 from replication-associated breaks. Thus, Brca1 might regulate Akt1 and 53BP1 in different steps during the HR process. The molecular details of these proteins in the HR process need further investigation in the future.
The tumor-suppressor Brca1 is frequently inactivated in human breast and ovarian cancers. Loss of the Brca1-BRCT domains that bind to Akt1 leads to mammary cancer formation in mice implicates the potential role of Akt1 in Brca1-related tumorigenesis. 3, 5, 20, 21 We implanted Brca1 D11/D11 MEFs in mice and generated tumors. The depletion of Akt1 in Brca1 D11/D11 MEFs significantly reduces tumor formation, which provides direct evidence that Akt1 is involved in Brca1-deficient cancer formation. We used the third-generation mTOR inhibitor, P529, which significantly suppresses tumor growth in mice with high expressing level of pAkt, such as Brca1-deficient tumors, suggesting a better therapeutic effect on Brca1-deficient tumors. 7 Our study here suggests that one therapeutic strategy to treat Brca1-deficient cancer might be in the systemic use of compounds that regulate the Chk1-Rad51 pathway. Thus, these results delineate the contributions of Brca1/Akt1 pathway to tumorigenesis and suggest the Akt1-Chk1-Rad51 pathway as novel therapeutic target for Brca1-deficient cancers.
MATERIALS AND METHODS
Cell culture, lentivirus infection, Western blot analysis and metaphase preparation
Brca1
D11/D11 deleted Brca1 exon 11 and expressed only the 3.9-kb transcript, which was verified by RT-PCR and sequencing (data not shown). Brca1 D11/D11 and Brca1 wt MEFs were cultured as described previously 8 and early passages of the MEFs were used. To generate lentiviral particles, 293T cells were cotransfected with the lentiviral vectors and compatible packaging plasmids mixture using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), and the lentivirus supernatant was collected 40 h after transfection. For virus infection, cells were exposed to lentivirus supernatant for 24 h in the presence of polybrene (Sigma, St Louis, MO, USA). Cytoplasmic and nuclear extracts from MEFs were extracted to conduct Western blot analysis as described previously. 8 Immunoprecipitation assay was performed and metaphases were prepared and imaged as described previously. 8, 22, 23 Antibodies and reagents Anti-Akt1, pChk1 (Ser-345) and Chk1 antibodies were from Cell Signaling Technology (Danvers, MA, USA). Anti-b-actin antibody was from Sigma. Anti-Rad51, goat anti-mouse IgG-HRP, goat anti-rabbit IgG-HRP, goat antimouse IgG-biotin and goat anti-rabbit-IgG-biotin second antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Vectastain ABC kit and DAB substrate kit were from Vector Laboratories (Burlingame, CA, USA). GFP, Chk1 and Akt1-shRNAs were obtained from Sigma.
Soft agar assays
For the Soft agar assay, cells (10 000/dish) were suspended in 2 ml of 0.3% agar and poured over a 3-ml 0.6% solidified layer of agar in 60 mm dishes. Cells were incubated for about 14-16 days until colonies were large enough to visualize. Colonies were observed under phase contrast microscope. Experiments were performed in triplicate.
Tumor growth experiments
Animal experiments were performed according to institutional guidelines for animal welfare. Female NOD.SCID/NCR mice of 6-8 weeks of age were purchased from NCI-Frederick Animal Production Program (Frederick, MA, USA). A total of 2 Â 10 6 Brca1 D11/D11 MEFs or MCF7 cells expressing GFP or Akt1 shRNA in 0.1 ml phosphate-buffered saline were mixed with equal volume of matrigel. The cell mixture was implanted into mouse breast fat pad. After 8-9 weeks, the tumors became rigid and the volume of tumor ((L Â W 2 )/2) is measured.
Recombination assays
Cells were plated at 2 Â 10 5 per well in six-well plates and was electroporated into various MEF cell lines after 24 h with various amounts of I-SceI. Cells were trypsinized 72h later, washed and fixed in phosphate-buffered saline for 15 min at room temperature. GFP þ cells were detected by flow cytometry using a FACS instrument.
Indirect immunofluorescence
Experiments were performed as described. [23] [24] [25] Briefly, for conventional immunofluorescence microscopy, the cells were examined with a Zeiss Axioskop fluorescence microscope equipped with a CCD camera (Ontario, NY, USA). Images were captured, pseudocolored and merged using IPLab image analysis software. At least 200 cells were analyzed for each experiment. The experiments were repeated at least three times.
